Intellia Therapeutics, INC Form 4 insider transactions

Edward J Dulac Iii, EVP, Chief Financial Officer of Intellia Therapeutics, Inc., sold 8,111 shares of common stock on July 22, 2026 for $11.25 per share.

Michael P. Dube, VP and Chief Accounting Officer of Intellia Therapeutics, reported a transaction involving the sale of 2,641 shares of common stock to cover tax obligations upon the vesting of RSUs.

Intellia Therapeutics EVP and CFO Edward J III Dulac sold 4,677 shares of common stock for $18 per share under a pre-arranged 10b5-1 trading plan.

Director Frank Verwiel was granted 9,200 restricted stock units and 13,300 stock options by Intellia Therapeutics.

Intellia Therapeutics director Georgia Keresty was granted 9,200 restricted stock units and 13,300 stock options on June 9, 2026.

Intellia Therapeutics director Jesse Goodman was granted 9,200 restricted stock units and 13,300 stock options on June 9, 2026.

Intellia Therapeutics director Brian Goff was granted 9,200 restricted stock units and 13,300 stock options on June 9, 2026.

Director Fred E. Cohen was granted 9,200 restricted stock units and 13,300 stock options by Intellia Therapeutics.

Intellia Therapeutics director William J. Chase was granted 9,200 restricted stock units and 13,300 stock options on June 9, 2026.

Director Muna Bhanji acquired 9,200 restricted stock units and 13,300 stock options in Intellia Therapeutics.

Intellia Therapeutics' Chief Medical Officer, David Lebwohl, received grants of restricted stock units and stock options effective March 1, 2026.

Intellia Therapeutics' EVP and CFO, Edward J. Dulac III, was granted 61,280 restricted stock units and 87,543 stock options on March 1, 2026.

Intellia Therapeutics CEO John M. Leonard sold 34,146 shares of common stock at $9.21 per share to cover tax withholding obligations related to RSU vesting.

Intellia Therapeutics' Chief Scientific Officer, Birgit C. Schultes, sold 8,508 shares of common stock at $9.21 per share to cover tax withholding obligations related to RSU vesting.

Intellia Therapeutics' EVP and General Counsel, James Basta, sold 10,397 shares of common stock at $9.21 per share to cover tax withholding obligations related to RSU vesting.

Intellia Therapeutics Director Fred E Cohen purchased 150,000 shares of common stock on January 5, 2026, increasing his beneficial ownership.

Intellia Therapeutics' Chief Medical Officer, David Lebwohl, sold 11,903 shares of common stock at $9.21 per share to cover tax withholding obligations related to RSU vesting.

Intellia Therapeutics EVP Eliana Clark sold 9,515 shares of common stock to cover tax obligations upon RSU vesting, not a volitional trade.

Intellia Therapeutics' EVP and CFO, Edward J. Dulac III, sold 6,379 shares of common stock to cover tax withholding obligations related to RSU vesting.

Intellia Therapeutics' VP, Chief Accounting Officer, Michael P. Dube, sold 2,989 shares of common stock at $9.21 per share to cover tax withholding obligations related to RSU vesting.

Intellia Therapeutics' President and CEO, John M. Leonard, sold a significant number of shares following the exercise of stock options under a pre-arranged 10b5-1 trading plan.

Intellia Therapeutics' Chief Scientific Officer, Birgit C. Schultes, reported a mandatory sale of 31 common shares to cover tax withholding obligations related to RSU vesting.

Intellia Therapeutics' VP, Chief Accounting Officer, Michael P. Dube, sold 1,871 shares of common stock at $17.38 per share to cover tax withholding obligations related to RSU vesting.

Intellia Therapeutics Director William J. Chase purchased 100,000 shares of common stock at an average price of $10.03, signaling confidence in the company.

Intellia Therapeutics' EVP and CFO, Edward J. Dulac III, reported a pre-planned mandatory sale of 7,462 common shares at $14.02 each to cover tax withholding obligations related to RSU vesting scheduled for July 2025.

Intellia Therapeutics' Executive Vice President and Chief Technical Officer, Eliana Clark, sold 1,022 shares of common stock on July 1, 2025, which were acquired through the company's Employee Stock Purchase Plan.

Intellia Therapeutics' VP, Chief Accounting Officer, Michael P. Dube, sold 2,503 shares of common stock at $9.95 per share to cover tax withholding obligations related to RSU vesting.

Intellia Therapeutics Director Jesse Goodman sold 3,094 shares of common stock in late June and early July 2025, pursuant to a pre-arranged 10b5-1 trading plan.

Intellia Therapeutics, Inc. Director Georgia Keresty was granted 8,000 restricted stock units and options to purchase 11,450 shares of common stock, effective June 11, 2025.

Intellia Therapeutics, Inc. Director Frank Verwiel reported the acquisition of 8,000 restricted stock units and stock options for 11,450 shares, increasing his beneficial ownership in the company.